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Abstract Recent evidence has demonstrated that the
complement cascade is involved in a variety of physiologic
and pathophysiologic processes in addition to its role as an
immune effector. Research in a variety of organ systems
has shown that complement proteins are direct participants
in maintenance of cellular turnover, healing, proliferation
and regeneration. As a physiologic housekeeper, comple-
ment proteins maintain tissue integrity in the absence of
inﬂammation by disposing of cellular debris and waste,
a process critical to the prevention of autoimmune disease.
Developmentally, complement proteins inﬂuence path-
ways including hematopoietic stem cell engraftment, bone
growth, and angiogenesis. They also provide a potent
stimulus for cellular proliferation including regeneration of
the limb and eye in animal models, and liver proliferation
following injury. Here, we describe the complement cas-
cade as a mediator of tissue growth and regeneration.
Keywords Complement  Growth  Regeneration 
Proliferation  Healing
Introduction
Since its discovery over 100 years ago, the complement
cascade has been recognized as an effector arm of innate
immunity, a set of serum proteins known to ‘‘complement’’
antibody-mediated pathogen clearance [1–3]. The com-
plement cascade includes 12 soluble proteins capable of
initiating a cytolytic response in the absence of other
humoral or cellular elements. Complement activation and
ampliﬁcation occur on the surface of the target cell, and are
initiated by the binding of one or more molecules of the
classical, alternative, or mannose-binding lectin pathways
[4]. The classical pathway destroys antibody-coated tar-
gets, apoptotic cells, gram-negative bacteria, and some
viruses [3]. The mannose-binding lectin pathway destroys
mannose-bearing pathogens [3]. Lastly, the alternative
pathway destroys a variety of infectious agents including
bacteria, viruses, and fungi, in addition to playing a role in
the immune surveillance of tumors [3]. Their convergence
into a ﬁnal common pathway results in creation of the
membrane attack complex (MAC), an amphipathic pore-
forming structure made up of C5b, C6, C7, C8, and mul-
tiple C9 molecules [2].
The traditional view of the complement cascade main-
tains that its role is to facilitate cellular killing and
inﬂammation.However,increasingevidencehaschallenged
this view in diverse ways. New sites of complement protein
synthesis and new locations for complement protein recep-
tors have been uncovered [3, 5]. Immune ‘‘imbalance’’ via
complement protein deﬁciency or dysregulation has been
implicated in the pathogenesis of numerous autoimmune
and non-immune diseases [3, 6]. Finally, complement pro-
tein regulation of cellular proliferation has been
demonstrated in a broad range of tissues [7]. This expo-
nential increase in our knowledge has established new roles
forthecomplement cascadeinbothtissuehealth anddisease
that expand upon its former designation as a mere immune
effector of host defense [3, 6, 8].
Evidence demonstrating the novel importance of
complement proteins has opened up especially exciting
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play important roles in developmental, proliferative, and
regenerative pathways in both injured and uninjured
tissue (Fig. 1). The dichotomy of ‘‘defender’’ and
‘‘healer’’ in a single system represents a major departure
from previous considerations of complement cascade-
mediated effects, and demands a reappraisal of tradi-
tional views. The following review offers insight into the
emerging body of research implicating complement
proteins as mediators of tissue health via their regulatory
effects on cell turnover, proliferation, maturation, and
regeneration.
The complement cascade as a physiologic housekeeper
Complement proteins are constitutively active,
facilitate cellular turnover, and prevent autoimmune
disease
Whether caused by endogenous or exogenous stimuli,
cellular injury is an inciting event for activation of the
classical, alternative, and mannose-binding lectin path-
ways. Complement proteins participate in multiple
phases of acute and chronic inﬂammation, including local
hemodynamic change, increased vascular permeability,
Fig. 1 The complement cascade is comprised of the Classical,
Alternative, and Mannose Binding Lectin pathways. Although the
activation and ampliﬁcation of each pathway is unique, they all
converge with cleavage of C3 into its main split products, C3a and
C3b, ultimately resulting in formation of the membrane attack
complex (MAC). Historically considered a critical arm of innate
immunity, emerging research has implicated various complement
proteins in proliferative and regenerative processes in organs
including bone, marrow, liver, and connective tissues. C1q maintains
appropriate turnover and clearance of cellular debris, while C4
maintains B cell tolerance, processes critical in the prevention of
autoimmune disease. Hematopoietic stem cell homing, chemotaxis,
engraftment, and mobilization are heavily inﬂuenced by the ana-
phylatoxins C3a and C5a. Additionally, they help facilitate
hepatocyte protection and regeneration in mouse models of toxic
and surgical injury. Limb and lens regeneration in urodele amphibians
are mediated by C3 and C5, while complement proteins such as C1s,
C5, C9, factor B and properdin are distributed throughout immature,
developing bone and appear to be important in osteogenesis. MBL
mannose-binding lectin, MASP mannose-binding lectin associated
serine proteases, HSC hematopoietic stem cell
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activation and upregulation, opsonization of pathogens,
and clearance of necrotic and apoptotic tissues [9]. The
potentially devastating effects of uncontrolled complement
activation and subsequent promotion of inﬂammation are
attenuated by a widespread network of inhibitory mem-
brane-bound complement receptors and soluble proteins.
These endogenous receptors and proteins prevent indis-
criminate complement mediated cellular destruction in
healthy host tissues by inhibiting excessive ampliﬁcation of
the complement cascade, thereby precluding formation of
the lytic MAC. Necrotic or apoptotic cells are susceptible
to complement mediated destruction due to their loss of
membrane-bound inhibitory molecules [6]. When these
checks and balances are lost, dysregulation of the com-
plement cascade facilitates a wide variety of autoimmune
diseases in which chronic inﬂammation is seen, including
glomerulonephritis [10–12], systemic lupus erythematosus
(SLE) [13], rheumatoid arthritis [14], and multiple sclero-
sis [15].
Research linking incomplete complement mediated
clearance of dead cells with subsequent autoimmune dis-
ease [16–20] argues that complement proteins play a vital
homeostatic mechanism. Termed the ‘‘waste-disposal’’
hypothesis, it has been proposed that complement protein
dysfunction or deﬁciency can lead to inadequate clearance
of cellular debris, consequently facilitating exposure to
potentially antigenic intracellular molecules [6]. Immature
dendritic cells then take up these autoantigens, mature, and
present them to T cells, leading to autoreactive B cell
stimulation and subsequent production of autoantibodies
[6]. Homozygous C1q deﬁciency provides a striking
example of complement related autoimmunity. Loss of this
initiator protein of the classical pathway almost invariably
leads to severe SLE [13].
Complement activation due to cell death can occur
secondary to inﬂammation or entirely independent of it.
Constitutive activation of the alternative pathway via
spontaneous C3 cleavage has been recognized for many
years [21]. Newer evidence suggests the classical cascade
is also constitutively active in humans and mice in an
antigen-independent manner, with blood stasis posited as a
possible inciting stimulus for its basal low-level activation
[22]. Based on the observation that ex vivo blood samples
from humans and mice exhibit spontaneous C3 fragment
formation, the authors investigated the complement acti-
vation pathway responsible for this effect by studying
plasma from mice and humans with speciﬁc complement
protein deﬁciencies. Spontaneous generation of C3 frag-
ments was abrogated in both C1q-deﬁcient humans and
complement knockout mice including C1qa
-/-,C 4
-/-, and
H2-Bf, C2
-/- mice [22]. While plasma from mice deﬁcient
in immunoglobulins (RAG
-/-) and factor B (Bf
-/-)
demonstrated spontaneous C3 fragment formation, it was
signiﬁcantly reduced compared to control mice. The
authors concluded that the alternative pathway likely
ampliﬁes the production of C3 fragments initiated by the
classical pathway [22]. Such continuous activation and
priming of the complement cascade might provide an
important physiologic mechanism that enhances clearance
of apoptotic and necrotic cells, better allowing for regula-
tion of tissue turnover.
However, complement protein dysfunction is not only
thought to contribute to autoimmune disease via insufﬁ-
cient clearance of debris; emerging evidence points to a
critical role for complement proteins in maintaining B cell
tolerance, thereby precluding production of autoantibodies.
In one elegant study, researchers investigated the role of
complement in the prevention or production of autoreactive
B cells in a mouse model of autoimmunity resembling SLE
[23]. They ﬁrst created a transgenic mouse model of B cell
tolerance in which the foreign protein hen egg lysozyme
(HEL), an antigen capable of inducing production of
autoreactive B cells, remained sequestered in the endo-
plasmic reticulum (ER) of all MHC-1 cells [24]. This ER-
restricted mHEL (mHEL-KK) transgenic mouse closely
recapitulates the pathogenesis of SLE by sequestering the
HEL autoantigen intracellularly. They then crossed C1q
deﬁcient mice (C1q
-/-) with MD4 Ig
HEL mice, a trans-
genic model encoding IgM
a and IgD
a speciﬁc to HEL.
Finally, they crossed these single transgenic mice (C1q
-/-
Ig
HEL) with mHEL-KK mice to create double-transgenic
C1q
-/- Ig
HEL/mHEL-KK mice. Armed with these mouse
models of autoimmunity resembling SLE, the authors
found that C1q facilitates potent downregulation of
numerous autoimmune phenomena. These C1q deﬁcient
mice demonstrated increased positive selection of B1b B
cells responsive to intracellular HEL, decreased negative
selection of conventional B cells, increased numbers of
plasma cells, and increased production of IgM autoanti-
bodies [23].
In addition to C1q, it has also been shown that the loss
of C4 or complement receptors 1 and 2 (CR1, CR2)
facilitates autoimmunity directly by inducing loss of B cell
tolerance and subsequent production of autoreactive B cells
[25, 26]. Furthermore, complement proteins are known
regulators of T cell proliferation [4, 27, 28]. Certain sub-
populations of T cells are inhibited directly by C1q,
preventing inappropriate self-attack [9, 29].
In total, the protean capabilities of various comple-
ment proteins in cellular clearance and modulation of the
adaptive immune response demonstrate critical roles in
the prevention of autoimmune disease. The continuous
activation of complement proteins maintains tissue
turnover as a physiologic event rather than a pathogenic
one.
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Complement proteins regulate hematopoietic stem cell
migration, homing, and engraftment
The continuous activation of complement proteins and split
products necessitates that healthy cells possess mechanisms
to protect themselves from accidental destruction. In non-
nucleated cells such as erythrocytes, inhibitory proteins,
includingdecay-acceleratingfactor(DAF),CD59,andCR1-
related gene y (Crry), prevent such destruction [30, 31].
Nucleated cells employ ion pumps that reverse MAC-
induced solute shifts, utilize ecto- and endo-proteases that
cleave complement components, and remove MACs from
their membrane surfaces [2, 32].
Unlike the defenses maintained by mature erythrocytes
and leukocytes against accidental complement destruction,
the interaction of complement proteins with immature
blood cells suggests a vital role in hematopoiesis, including
mobilization and localization of progenitor cells. As a
fundamental component of innate immunity, complement
proteins become activated in cellular injury, and it has been
suggested that hematopoietic stem cells (HSCs) likely play
an important and concomitant role in this response to injury
[33].
Extensive research into complement protein C3a has
revealed a wealth of information on its roles in bone
marrow engraftment and HSC mobilization. Progenitor
cells including myeloid, erythroid, and megakaryocytic
blasts, as well as human CD34? cells, were all found to
express the C3a receptor (C3aR) [34]. When stimulated by
C3a secreted from bone marrow, THP-1, Jurkat, and PB-1
cell lines did not demonstrate a chemotactic response.
However, when stimulated in the presence of stromal-cell
derived factor 1 (SDF-1), all cells demonstrated increased
chemotaxis in response to C3a [34]. Human CD34? cells
and their progenitors exhibited similar behavior: C3a
increased SDF-1 mediated chemotaxis in mature CD34?
cells and CD34? progenitors committed along all hema-
topoietic lineages [34]. These synergistic effects of C3a
and SDF-1 suggest that C3a enhances the SDF-1-CXCR4-
dependent axis in HSCs. Notably, the authors found that
C3a had no inﬂuence over HSC survival or proliferation
[34].
C3a also appears to be important in HSC engraftment.
C3a aids SDF-1 mediated adhesion of human CD34? cells
to vascular cell adhesion molecule 1 (VCAM-1), and when
primed with C3a, bone marrow Sca-1
? cells show an
increased speed of engraftment in irradiated mice [34].
Studies of granulocyte colony-stimulating factor (G-CSF),
an established mobilizer of HSCs [33], further delineate
the role of C3a. In C3
-/- and C3aR
-/- mice, G-CSF
signiﬁcantly increased mobilization of stem cells when
compared to wild type mice; however, when given a C3aR
antagonist, wild type mice also showed increased mobili-
zation [35]. Additionally, wild type mice given C3aR
-/-
HSCs were more sensitive to G-CSF mobilization versus
C3aR
-/- mice given wild type HSCs, again indicating the
importance of C3a/C3aR interaction in engraftment, likely
through increased sensitization to the effects of SDF-1
[35]. Similarly decreased HSC engraftment was observed
when C3
-/- mice were transplanted with wild type HSCs
[36].
These results, however, contrast with those of Hon-
czarenko et al. [37] showing that human and mouse bone
marrow progenitor cells and B lineage cells demonstrate
enhanced SDF-1 mediated migration and engraftment in
the presence of C3a independent of the C3a receptor. They
found no evidence of the C3a receptor on bone marrow
stem cells and B lineage cells, and could not abrogate the
chemotactic effects of C3a using a C3a receptor inhibitor
or a C3aR
-/- mouse [37]. They instead discovered that
C3a binds SDF-1 and enhances its afﬁnity for CXCR4 [37],
presumably increasing or enhancing activity of this axis.
As the authors note, apparent discrepancies in the presence
of C3aR on human CD34? cells and HSCs may be due to
the manner in which they were collected and treated [37].
To clarify this seemingly discrepant data and the
importance of the C3a receptor in HSC behavior, Wys-
oczynski et al. studied the role of the C3a/C3aR interaction
in HSC retention. When compared to wild type murine
HSCs, C3aR
-/- HSCs demonstrate delayed bone marrow
homing and engraftment in lethally irradiated mice [38].
Human HSCs exhibit similar behavior: when exposed to
C3aR antagonist and then transplanted into NOD/SCID
mice, defective colony growth was observed following
recovery and plating [38]. They also found that C3a
stimulates matrix metalloprotease-9 (MMP-9) production
by wild type HSCs at the mRNA and protein levels, but not
in C3aR
-/- HSCs. This is believed to be important due to
the role of MMP-9 in facilitating HSC migration through
extracellular matrix and into tissues such as bone marrow
[34].
These most recent data reconcile a dual role for C3a in
HSC behavior that is both dependent and independent of
the C3a receptor. It appears that the C3a/C3aR interaction
is critical to HSC engraftment through mechanisms
involving tissue migration and adhesion, whereas homing
and chemotaxis are primed via SDF-1-CXCR4 sensitiza-
tion by C3a independent of its receptor.
Interestingly, complement protein C5 appears to have an
opposite effect on HSCs compared to C3a: C5
-/- mice
demonstrate greatly reduced HSC mobilization in response
to G-CSF and zymosan, an activator of the alternative
pathway [39]. Interestingly, murine HSCs do not express
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mediated chemotaxis like C3a [40]. Instead, it appears that
C5a indirectly induces HSC egress via granulocytes. C5a
stimulates release of their proteases, which in turn interrupt
pathways such as SDF-1-CXCR4 that help sequester HSCs
in bone marrow [33, 40]. Released proteases also appear to
enhance the response of HSCs to SDF-1 gradients, pro-
moting their release from bone marrow into the peripheral
circulation [40].
Further interest in the interaction between complement
proteins and hematopoietic stem cells has centered on the
identiﬁcation and behavior of AA4. This murine stem cell
antigen is believed to be homologous to human C1qRP, a
receptor for C1q that is expressed in phagocytic myeloid
progenitors, endothelial cells, and platelets [41]. In the
adult mouse, AA4 expression has been identiﬁed in lung,
heart, and bone marrow; in the fetus, expression occurs in
vascular endothelial cells, aorta-associated hematopoietic
clusters, and in all fetal liver hematopoietic stem cells [42].
Given its homology to mouse AA4, C1qRP may play a
similar developmental role in humans, including the
homing of hematopoietic progenitors to the fetal liver, and
endothelial cell migration, adhesion, and formation of
intercellular junctions [42].
Complement proteins aid cartilage turnover and bone
development
A well-delineated sequence of events comprises endo-
chondral bone formation in which three distinct zones of
resting, proliferating and hypertrophic chondrocytes
develop. However, the factors governing their growth and
the subsequent vascular and mesenchymal cell invasion
that immediately precedes matrix remodeling and bony
deposition remain incompletely understood. Complement
protein induction of cartilage and extracellular matrix
degradation has been appreciated for several decades [43],
but more recent research has yielded information about the
distribution of complement proteins in areas of cartilage
and bone and their putative function.
C1s possesses the ability to degrade Type 1 and 2
collagen [44]. Immunohistochemical analysis of the pri-
mary ossiﬁcation center of the human femur revealed that
C1s co-localizes with MMP-9 throughout this region,
including hypertrophic chondrocytes, mesenchymal cells
and the extracellular matrix [44]. C1s can also cleave the
zymogen of MMP-9 and activate its protease activity
[44]. Their co-localization implies a coordinated role in
the turnover of cartilage to bone [44]. Another component
of the C1 complex, C1q, also appears important in
osteogenesis. C1q levels increase with differentiation of
hypertrophic chondrocytes in hamster models of osteo-
genesis [45, 46].
The alternative pathway may also be involved in bone
formation. Among fetal rat tibias and femurs, C3 and factor
B are distributed in the resting and proliferating zones,
properdin in the resting and hypertrophic zones, and C5
and C9 in the hypertrophic zones [43]. Their differential
localization intimates participation in bone formation and
remodeling, vascular invasion, and extracellular matrix
remodeling [7, 43]. Taken together with evidence of clas-
sical pathway involvement, complement proteins can
stimulate turnover of cartilage to bone.
Complement also participates in vitamin D3 regulation
of bone. Vitamin D3 is known to induce bone production of
C3. Murine osteoblastic cells and bone marrow derived
stromal cells (ST2) release C3 in response to D3 in vitro
[47, 48], and vitamin D3 additionally induces murine bone
production of C3 in vivo [49]. Among bone marrow cul-
tures grown with vitamin D3, C3 can be found in
macrophage-like mononuclear cells, progenitor cells that
can form mature osteoclasts [50]. These cells also express
receptors for C3. When exposed to anti-C3 receptor anti-
bodies in the presence of vitamin D3, formation of
osteoclasts is inhibited [50]. Furthermore, while vitamin
D3 binding appears to inhibit macrophage colony stimu-
lating factor (M-CSF), a growth factor critical in osteoclast
development, C3 co-exposure combats this inhibitory
effect in vitro and potentiates the effects of M-CSF [50].
Complement proteins mediate limb and lens
regeneration in urodeles
Urodele amphibians are known for their remarkable ability
to regenerate injured tissues, including their limbs, tail, eye
structures, and some internal organs [51]. A recent series of
fascinating studies strongly implicates the complement
cascade as a mediator of these regenerative pathways.
In response to injury, a complicated progression occurs
in which mature cell types present at the site of injury
undergo dedifferentiation, multiplication, and re-differen-
tiation into the blastema, a stem-cell like structure [52].
Blastema cells are responsible for repopulating and
reforming old structures by redifferentiation into mature
tissues such as muscle, bone, and connective tissue. In one
of the earliest studies on the subject, the C3 gene was
discovered to be speciﬁcally expressed by urodele blastema
cells at the transcript and protein level as evidenced by in
situ hybridization and detection of antibodies against C3
[52]. Furthermore, C3 protein was present in blastema cells
of myogenic lineage [52], conﬁrming earlier experiments
demonstrating diverse complement protein expression by
myoblast cell cultures [53, 54]. C3 localizes to regenerating
tissues and not normal tissue, suggesting a primary role in
mediating regeneration [52]. It has been postulated that
complement activation attracts a coordinated inﬁltration of
Complement and regeneration 901macrophages responsible for protection from further
injury-related damages [52]. Because the complement
cascade interacts with numerous extracellular structural
proteins responsible for cell anchoring and intercellular
connections, including integrins, laminin, and ﬁbronectin,
it is possible that complement proteins facilitate regener-
ation of intercellular connections and ensuing cellular
communication [52].
C5 is also an important factor in newt limb regeneration.
While C3 shows robust immunohistochemical staining
within the blastema and some staining in wound epithe-
lium, C5 is absent from the blastema but strongly present in
wound epithelium at all stages of limb regeneration [51].
The unique distributions of C3 and C5 are thought to arise
from their differential roles in the regenerative process.
This speciﬁcity is similarly seen in the newt eye: both
proteins are present in the cornea and iris, but C5 alone is
located in the lens vesicle [51]. Neither C3 nor C5 are
present in the intact lens. Interestingly, while both C3 and
C5 mRNA were detected in the regenerating lens vesicle
by in situ hybridization, only C5 translation to protein was
appreciated, indicating translational or post-translational
modiﬁcations that differentially localize it to specialized
areas [51].
Complement proteins facilitate liver regeneration
The human liver is one of few human tissues capable of
near complete organogenesis in response to a variety
of endogenous and exogenous insults [55, 56]. Initiation
of liver regeneration is multifactorial, as growth factors,
hormones, and immune mediators have all been implicated
[56]. Interestingly, stem cells do not have an exclusive role
in liver regeneration, despite the liver’s ability to repopu-
late all cell types intrinsic to the healthy organ, including
hepatocytes, biliary epithelial cells, fenestrated endothe-
lium, Kupffer cells and cells of Ito [56].
Several studies predating the established link between
the complement cascade and liver regeneration suggested
that complement proteins might play a role. One group of
researchers found that Kupffer cells and hepatic stellate
cells secrete prostanoids in response to C5a/C5aR binding
on their surface, causing an increase in glucose production
by adjacent hepatocytes and a local decrease in blood ﬂow
[57, 58]. This process is considered important in the pro-
vision of fuel necessary for the rapid metabolism seen in
liver regeneration [7]. Another group highlighted the role
of C5a in defense against liver injury by demonstrating that
C5aR mRNA and protein is induced in hepatocytes in
response to exogenous IL-6 in rats [59]. By responding to
inﬂammation with functional C5a receptors, these hepato-
cytes are believed to prime themselves for defense against
injury by allowing more direct facilitation of C5a induced
glucose production [59]. Ultimately, the complexity of IL-
6 actions and synthesis makes it difﬁcult to conclude the
exact nature of its inﬂammatory properties and its effects
on the complement cascade.
The liver is the body’s primary site of complement
protein synthesis, and a growing body of evidence now
deﬁnitively demonstrates that complement proteins C3a
and C5a are critical to liver regeneration following injury.
Following experimental liver injury induced by carbon
tetrachloride (CCl4), a well-characterized hepatotoxin that
induces liver necrosis and apoptosis, C5
-/- mice showed
signiﬁcantly diminished liver regeneration compared to
wild type, C5 sufﬁcient mice [55]. The hepatocytes in
C5
-/- mice demonstrated signiﬁcantly delayed entry into
S-phase of the cell cycle, decreased mitotic activity, per-
sistent necrosis, and decreased proliferation. Restoration of
murine C5 or C5a restored the regenerative response [55].
To corroborate the involvement of the C5a/C5aR interac-
tion in promoting regeneration, the authors also
demonstrated that antagonist blockade of C5aR in wild
type mice diminishes liver regeneration [55]. A related
study demonstrated the presence of C5a receptor on
regenerating hepatocytes, noting its levels were greatly
upregulated following hepatectomy or cell culture induced
stress [60]. Furthermore, C5a binding to C5aR induced
expression of mRNA for hepatocyte growth factor (HGF)
and its corresponding c-MET receptor [60], proteins known
to induce mitosis and liver regeneration [56].
C3 has also been shown to play a critical role in liver
regeneration. For example, one study found that C3
-/-
mice and C3aR
-/- mice exposed to CCl4 exhibited greatly
reduced hepatic regeneration [61]. Among C3
-/- mice,
systemic introduction of C3a restored hepatic regeneration,
reducing the possibility of downstream C5 effects given
that these mice are intrinsically deﬁcient in the C3b frag-
ment needed to form the C5 convertase [61]. C3aR
-/-
mice displayed delayed hepatocyte S-phase entry and
received no beneﬁt from systemic C3a reconstitution, both
suggesting that C3a exerts its regenerative effects through
C3aR. Interestingly, deposition of C3 split products in
injured liver occurred in a biphasic pattern following CCl4
exposure: C3a deposition peaked within the ﬁrst 3 h, while
C3b deposition peaked much later, typically between 24
and 48 h [61]. The authors postulate that C3a may there-
fore have a priming effect on injured liver that activates
critical cell cycle pathways including the STAT-3 and NF-
jB transcription factors [61, 62]. Subsequent C3b deposi-
tion likely aids the clearance of dead hepatic cells [61].
Recent evidence indicates that complement proteins aid
the survival of proliferating liver cells in addition to acting
as stimuli for healing and regeneration. Mice doubly
deﬁcient in C3 and C5 (C3/C5
-/-) demonstrate marked
hepatocyte apoptosis following partial hepatectomy. While
902 M. J. Rutkowski et al.reconstitution of C3 or C5 attenuates this injury, reconsti-
tution of both almost completely prevents apoptotic injury
[63]. This phenomenon may be due in part to the role of
complement in promoting inﬂammatory cytokines that
arise in the setting of liver injury and aid anti-apoptotic
signalling [63]. For example, loss of serum IL-6 induction
in C3/C5
-/- mice undergoing partial hepatectomy inter-
rupts cell signaling through the JAK1 pathway via loss of
JAK1 phosphorylation and decreased activation of STAT-3
[63]. Additionally, C3
-/- mice demonstrate lower activity
of the PI3K/Akt pathway, causing a decrease in mamma-
lian targets of rapamycin (mTOR) signaling [63, 64],
another pathway strongly associated with cellular prolif-
eration [65].
Conclusion
Abundant evidence indicates that the complement cascade
can no longer solely be considered an effector of innate
immunity. In addition to performing a variety of physio-
logic housekeeping functions, complement proteins clearly
respond to tissue injury with induction of cellular prolif-
eration and regeneration across a diverse array of organ
systems, as evidenced by in vitro and in vivo research.
These observations provide a previously unrecognized
mechanism for tissue healing. As our understanding of the
complement cascade’s capabilities increases, so too does
the promise of therapeutic interventions that enhance the
beneﬁcial effects of complement proteins and attenuate
their negative ones.
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